{
    "nct_id": "NCT06764485",
    "official_title": "A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge",
    "inclusion_criteria": "Inclusion Criteria\n\n* Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features.\n* Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computed tomography/magnetic resonance imaging (CT/MRI).\n* Participants must be asymptomatic or mildly symptomatic from prostate cancer with score on Brief Pain Inventory - Short Form (BPI-SF) that must be < 4.\n* Participants must have had previous treatment with an androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, or darolutamide).\n\nExclusion Criteria\n\n* Participants must not have impaired cardiac function or clinically significant cardiac disease.\n* Participants must not have any brain metastasis.\n* Participants must not have any liver metastasis.\n* Participants with superscan on technetium-99m (Tc-99m) radionuclide bone scans.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}